SEC Filing Summary

Charles M. Baum, a director at Acrivon Therapeutics, Inc., acquired 9,366 shares of Common Stock on May 18, 2026, with a transaction value of $0. This acquisition was made through restricted stock units (RSUs) that vest on May 18, 2027, contingent upon continued service. Following this transaction, Mr. Baum holds 9,366 shares directly. The filing was made on Form 4, with the signature date of May 20, 2026.